Aaron Fulgham

A highly motivated in vivo pharmacologist with over 15 years of experience in oncology research and pre-clinical development of novel biologics and small molecule therapeutic agents. In‐depth knowledge and expertise in planning, executing, and interpreting animal studies (including pharmacodynamic, pharmacokinetic, and in vivo immune-oncology efficacy studies in syngeneic and xenogeneic animal models IBD colitis, adoptive cell transfer and neuronal manipulation studies). Significant experience developing in vitro bioanalytical and molecular assays to elucidate drug mechanism of action and guide biomarker strategy. Organized team leader with exceptional ability to build positive rapport, inspire trust, and guide teams toward achieving organizational goals. Strong facilitator adept at working cross-departmentally with co-management and top-level leadership. Excellent trainer and mentor. Versatile Senior Manager specializing in mentorship, teamwork, and transparency. Skilled at planning, implementing, and overseeing key improvements to drive team growth and efficiency. History of cultivating an open culture with free exchange of information. Pursuing new professional challenges with a growth-oriented company.

• Dosage and Administration of Anti-c-Met, Anti-EpCAM Bispecific Antibodies, Uses Thereof and Methods of Treatment Therewith (WO2016209887 A1)
• Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) and/or its cognate receptor, c-met (WO 2016054414 A1)

• MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM . PNAS April 9, 2019 116 (15) 7533-7542
• Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody Seribantumab (MM-121): Systems Biology and Applications (2017) 3, 16034.
• Mechanistic characterization of MM-131, a bispecific antibody that blocks c-Met signaling through concurrent targeting of EpCAM: AACR Annual Meeting, April 18 - 22, 2015, Philadelphia, Pennsylvania
• The c-Met targeting antibody MM-131 reverses c-Met driven tumor cells resistance to standard-of-care-drugs: EACR-AACR, June 20-23, 2015, Florence Italy
• EORTC – NCI – AACR Symposium on Molecular Targets and Cancer TherapeuticsEORTC – NCI – AACR Symposium on Molecular Targets and Cancer TherapeuticsEORTC – NCI – AACR Symposium on Molecular Targets and Cancer TherapeuticsMM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigen:26th EORTC-NCI-AACR, November 18-21, 2014 Barcelona, Spain
• MM-121, an anti-ErbB3 antibody, inhibits PI3K/AKT signaling and viability in platinum-resistant ovarian cells and primary ascites derived from chemo-resistant ovarian cancer patients: EORTC – NCI – AACR, 2012 Dublin, Ireland EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics
• Prediction of xenograft response to MM-121, an anti-ErbB3 inhibitor, using computational modeling and measurements of five biomarkers: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC.
• An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation: Cancer Res. 2010;70(6):2485-2494.